CEBPG demonstrates oncogene functions and modulates the expression of genes involved in cervical cancer related pathways Authors: Tingting Qi, Jing Yang, Guzhalinuer Abulizi Published: 2026 ABSTRACT BackgroundCervical cancer is a major cause of female cancer incidence and mortality globally. Targeted therapy shows promise with higher efficacy and fewer side effects, yet effective biomarkers are needed. CEBPG, a bZIP transcription factor, has attracted attention as a potential biomarker and therapeutic target. It promotes tumor growth in various cancers, but its role in cervical cancer is unclear. The aim of this study is to investigate the expression, biological function, and transcriptional regulatory mechanisms of CEBPG in cervical cancer.MethodsThis study analyzed CEBPG expression in cervical cancer using The Cancer Genome Atlas (TCGA) data, overexpressed it in HeLa cells, and conducted proliferation, apoptosis, migration, and invasion experiments. RNA sequencing (RNA-seq) revealed CEBPG’s transcriptional regulatory network.ResultsOur findings revealed that CEBPG expression was significantly higher in cervical cancer than in normal tissues. Overexpression of CEBPG in HeLa cells significantly enhanced proliferation, migration, and invasion while repressing apoptosis. RNA-seq analysis identified numerous differentially expressed genes (DEGs) enriched in pathways critical for tumorigenesis and progression, such as angiogenesis, cell proliferation, and migration. Bioinformatics analysis identified 27 potential transcriptional targets of CEBPG, several of which were associated with poor prognosis and higher expression in cervical cancer tissues.ConclusionsCEBPG may contribute to malignant phenotypes in cervical cancer, potentially through the transcriptional regulation of specific target genes. The high expression of CEBPG in cervical cancer and its demonstrated role in promoting malignancy through transcriptional regulation provide novel insights into the molecular mechanisms of cervical carcinogenesis and progression. This offers directions for further exploration of CEBPG as a potential therapeutic target and biomarker. Highlight box Key findings • CEBPG expression is markedly higher in cervical cancer than in normal tissues. • Overexpression of CEBPG promotes proliferation, migration, and invasion while inhibiting apoptosis in HeLa cells. • CEBPG regulates 27 potential transcriptional targets, including ANTXR2, PDZK1IP1, and SULF1, which are associated with poor prognosis in cervical cancer. What is known and what is new? • CEBPG is known to promote tumor growth in various cancers, but its role in cervical cancer and the underlying transcriptional regulatory mechanisms remain unclear. • This study demonstrates that CEBPG drives malignancy in cervical cancer by regulating the expression of target genes involved in proliferation, migration, invasion, and apoptosis, revealing a novel transcriptional regulatory network of CEBPG in cervical cancer. What is the implication, and what should change now? • CEBPG represents a candidate prognostic indicator and potential therapeutic target in cervical cancer. • Future studies should validate the transcriptional regulatory relationships between CEBPG and its target genes, and explore its potential in targeted therapy strategies. Introduction In 2020, approximately 604,100 new diagnoses and 341,800 deaths from cervical cancer were recorded worldwide, accounting for the fourth highest incidence and mortality rates among all cancers affecting women (1). Squamous cell carcinoma accounts for 80% of all cervical cancers, while adenocarcinoma makes up 20%. The 5-year survival rate for patients with metastatic or recurrent cervical cancer is below 17% (2,3). Even with significant advancements, approximately 30% of patients will experience disease recurrence (4). Compared to current surgical interventions, radiotherapy, and chemotherapy, targeted therapy is expected to offer higher efficacy and fewer adverse reactions (5). There is a pressing need for more effective biomarkers to more accurately identify patients who will derive the greatest benefit from all of the aforementioned therapies, as well as pinpointing those with specific molecular characteristics who may benefit from alternative targeted treatments. CCAAT/enhancer-binding protein gamma (also known as CEBPG) belongs to the leucine zipper (bZIP) family of transcription factors. Depending on its heterodimeric partners, specific gene promoters, as well as the spatiotemporal and cellular context, it can either activate or repress gene transcription (6,7). CEBPG is being widely studied as a prognostic and therapeutic candidate in cancer progression. It inhibits ferroptosis and accelerates the progression of ovarian cancer by transcriptionally regulating the expression of SLC7A11 (8). CEBPG promotes the proliferation of acute myeloid leukemia cells by activating EIF4EBP1 (9). Additionally, it facilitates lung cancer metastasis by upregulating the expression of CERS6 (10). However, despite numerous studies revealing the role of CEBPG in promoting tumor growth, its expression level, biological function and mechanism of action in cervical cancer remain unclear. We analyzed CEBPG expression in cervical cancer using data from The Cancer Genome Atlas (TCGA) database. Subsequently, we overexpressed CEBPG in the cervical cancer cell line HeLa, followed by conducting experiments on cell proliferation, apoptosis, migration, and invasion. Additionally, we explored the regulatory network of CEBPG through RNA sequencing (RNA-seq). Our findings revealed that CEBPG was highly expressed in cervical cancer. Elevated CEBPG expression in HeLa cells enhanced cell growth, motility, and invasiveness while decreasing cell death. It is suggested that CEBPG may exert oncogenic effects in cervical cancer by regulating gene expression. We present this article in accordance with the MDAR reporting checklist (available at https://tcr.amegroups.com/article/view/10.21037/tcr-2026-0938/rc). Methods CEBPG overexpression plasmid The pcDNA3.1-3xFlag-CEBPG overexpression plasmid and the corresponding control plasmid [empty vector, negative control (NC)] were obtained from Youbio Biotech (Changsha, China). The coding sequence corresponds to NM_001806.4. Cell culture and transfections Hela cells (CL-0101, Procell, China) were incubated at 37 ℃ in 5% CO2 within MEM medium (PM150410, Procell, China) supplemented with 10% fetal bovine serum (FBS, 10099-141, Gibco, China), 100 µg/mL streptomycin, and 100 U/mL penicillin (SV30010, Hyclone, USA). Cells were transfected with Lipofectamine and harvested at 48 h for reverse transcription quantitative polymerase chain reaction (RT-qPCR) and Western blot. Reverse transcription and qPCR Reverse transcription was carried out with a cDNA synthesis kit (R323-01, Vazyme, China). Real-time PCR was run on an ABI QuantStudio 5 platform with SYBR Green detection. The amplification protocol consisted of 95 ℃ for 10 min, then 40 cycles of 95 ℃ for 15 s and 60 ℃ for 1 min. All reactions were run in triplicate. Primer sequences are provided in Table 1. Table 1Oligonucleotide primers used for qPCR analysisGenePrimerSequence (5'-3') GAPDH ForwardGGTCGGAGTCAACGGATTTGReverseGGAAGATGGTGATGGGATTTC CEBPG ForwardTGCTGACCAAGGAATTAAGTGTReverseTCGCCATCTGCTGTCGTATqPCR, quantitative polymerase chain reaction. Oligonucleotide primers used for qPCR analysis qPCR, quantitative polymerase chain reaction. Western blot For protein extraction, HeLa cells were lysed on ice for 30 min in Radioimmunoprecipitation Assay (RIPA) buffer (PR20001, Proteintech, China) with a protease inhibitor cocktail (4693116001, Sigma, USA). Lysates were heated at 100 ℃ for 10 min in loading buffer (P1040, Solarbio, China), run on 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS‑PAGE) gels, and blotted onto polyvinylidene difluoride (PVDF) membranes (ISEQ00010, Millipore, USA). Membranes were blocked (1 h) then probed overnight at 4 ℃ with anti-Flag (1:1,000, mouse-derived, 66008-3-Ig, Proteintech, China) and anti-ACTIN (1:5,000, rabbit-derived, 20536-1-AP, Proteintech, China). Subsequently, they were incubated with horseradish peroxidase-conjugated secondary antibodies (anti-rabbit, 1:10,000, SA00001-2, Proteintech, China or anti-mouse, 1:10,000, AS003, ABclonal, China) at room temperature for 45 min. Signals were detected with ECL reagent (P0018FM, Beyotime, China). Cell viability assay HeLa cell viability was evaluated using a Cell Counting Kit-8 (CCK-8) kit (HY-K0301, MCE, Shanghai, China), with cells plated at 4×104 per well in 24‑well plates. Absorbance at 450 nm was read at 0, 24, 48, and 72 h on a microplate reader (ELX800, Biotek, USA). Background absorbance was subtracted, and values were normalized to controls. Flow cytometric apoptosis assay Apoptosis was evaluated using an Annexin V-fluor647/PI kit (40304ES60, keyGEN, China). HeLa cells plated at 8×104/well in 12‑well plates and subjected to designated treatments were harvested and then stained sequentially with 5 µL Annexin V‑fluor647 (15 min, dark) and 10 µL PI (15 min). Stained cells were then analyzed on a flow cytometer (FACSCanto, BD, USA). Transwell migration assay Migration was assessed using transwell chambers (3422, Corning, USA). HeLa cells in 0.2 mL serum‑free medium were placed in the upper transwell chambers (8 µm pores), with 600 µL of 10% FBS medium in the lower compartment as a chemoattractant. NC and CEBPG plasmids were transfected, and cultures were maintained at 37 ℃ with 5% CO2 for 48 h. cells on the upper membrane surface were removed. Migrated cells on the lower side were fixed, stained with crystal violet, and counted. Transwell invasion assay Invasion ability was assessed using Matrigel-coated transwell chambers. After Matrigel (356234, BD Biosciences, USA) solidification, HeLa cells (8×104 in serum‑free medium) were loaded into the upper inserts, with 10% FBS in the lower wells. Following transfection with NC or CEBPG plasmids and 48 h incubation, non‑invaded cells on the upper membrane were removed. Invaded cells were stained with crystal violet and counted. RNA isolation and sequencing Total RNA was extracted using TRIZOL (15596-018, Ambion, USA), followed by chloroform extraction and treatment with RQ1 DNase (M6101, Promega, USA) to eliminate DNA. RNA purity (A260/A280) and integrity (agarose gel) were assessed. Library preparation and sequencing were performed by Wuhan Ruixing Biotechnology Co., Ltd. (Wuhan, China). Poly(A) mRNA was enriched, fragmented, and reverse‑transcribed to double‑stranded cDNA, followed by end repair, adapter ligation, and PCR amplification. Paired‑end 150 nt sequencing was conducted on a DNBSEQ‑T7 system. RNA‑seq data processing Reads with more than two ambiguous bases (N) were filtered out. Adaptor sequences and low‑quality bases were trimmed using FASTXToolkit (v0.0.13), and reads shorter than 16 nt were removed. The remaining clean reads were aligned to the GRCh38 reference genome using HISAT2 (v2.2.1) (11) , allowing up to four mismatches. Only reads with unique alignment were kept for transcript quantification, and expression levels were calculated as transcripts per million (TPM). Differentially expressed genes (DEGs) analysis Identification of DEGs was performed using DESeq2 (1.38.3) (12). Statistical significance was determined by an adjusted P value <0.05 and a fold-change cutoff of >1.5 for upregulation or <0.67 for downregulation. Functional enrichment analysis The KOBAS 2.0 server was used to retrieve enriched Gene Ontology (GO) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways for the target genes (13). Statistical significance for each term was evaluated with the hypergeometric test, followed by false discovery rate (FDR) adjustment using the BenjaminiHochberg method. Additionally, Gene Set Enrichment Analysis (GSEA) was conducted to identify broader functional changes between the Mets and Primary groups. Using the clusterProfiler package (version 4.6.2) (14), genes were ranked based on their differential expression [|log2 fold change (FC)|], and enrichment significance was evaluated against the Hallmark gene sets from the Molecular Signatures Database. Predicting transcriptionally regulated target genes of CEBPG The transcriptionally regulated target genes of CEBPG were sourced from the ENCODE database (https://www.encodeproject.org/), the TFTG database (http://tfbsdb.systemsbiology.net/download), and the TRRUST database (https://www.grnpedia.org/trrust/). Analysis of CEBPG ChIP-seq data To further investigate the direct binding of CEBPG to the promoters of its potential targets, we downloaded CEBPG ChIP-seq data from the GEO database, including the Input control sample (GEO: GSE95997) and the CEBPG IP sample (GEO: GSE96281), both derived from HepG2 cells (15). For ChIP-seq data processing, sequencing reads were mapped to the GRCh38 reference genome via Bowtie2 (16), and only reads with unique alignments were selected for downstream analyses. Putative CEBPG-binding peaks were called using MACS (version 1.4) (17), with the Input sample used as background. DeepTools (18) was employed to annotate genomic features—particularly the distribution of peaks relative to transcription start sites (TSS)—and to generate binding profile visualizations. Motif enrichment analysis within the peaks was carried out using HOMER (19). These analyses were performed to evaluate CEBPG occupancy at the promoter regions of the candidate target genes identified in our RNA-seq data. Analysis of cervical cancer data The association of PDZK1IP1 and ANTXR2 expression levels with patient overall survival in cervical squamous cell carcinoma (CESC) patients were evaluated using the Kaplan-Meier plotter (https://kmplot.com/analysis/). The verification of CEBPG, PDZK1IP1, and EHD3 expression between tumor and normal samples was conducted using the GEPIA2 (http://gepia2.cancer-pku.cn) database, the UALCAN platform (http://ualcan.path.uab.edu) and Human Protein Atlas (HPA) (https://www.proteinatlas.org/) database. The study was conducted in accordance with the Declaration of Helsinki and its subsequent amendments. Statistical analysis All plots, including pattern diagrams and bar graphs, were created with R (version 4.3.3) in RStudio. Results are expressed as mean ± standard error of the mean (SEM). Group comparisons were performed using two‑tailed Student’s t‑test. Results CEBPG exhibits high expression in cervical cancer To clarify CEBPG expression in cervical cancer tissues, we conducted an analysis of its expression levels using cervical cancer data (CESC) from the TCGA database. The results demonstrated that CEBPG was highly expressed in cervical cancer tissues, and its expression was significantly higher than that in the normal group across different stages (Figure 1A,1B). Furthermore, we analyzed CEBPG expression stratified by lymph node metastasis status and found that CEBPG expression was significantly elevated in cervical cancer patients both with (N1) and without (N0) lymph node metastasis compared to normal tissues; however, no significant difference was observed between the N0 and N1 groups (Figure 1C). Kaplan-Meier survival analysis further revealed that patients with high CEBPG expression had significantly poorer overall survival compared to those with low expression (Figure 1D). Furthermore, in the HPA database, the expression level of CEBPG was also found to be higher in cervical cancer tissues compared to normal tissues (Figure 1E). These results indicate that CEBPG is upregulated in cervical cancer tissues. CEBPG demonstrates elevated expression in cervical cancer tissues. (A) CEBPG expression levels in TCGA-CESC normal and tumor samples. (B) Boxplots showing mRNA expression level of CEBPG in different stages of cervical cancer. (C) Boxplots showing CEBPG expression stratified by lymph node metastasis status (normal, N0, N1). (D) Kaplan-Meier survival curve of CESC patients stratified by high versus low CEBPG expression. (E) The immunohistochemistry analysis of CEBPG in CESC or normal (image available from https://www.proteinatlas.org/ENSG00000153879-CEBPG/cancer/cervical+cancer#img) (scale bar: 50 µm). *, P<0.005; ***, P<0.001. CESC, cervical squamous cell carcinoma; CI, confidence interval; DFS, disease-free survival; HR, hazard ratio; N, node; T, tumor; TCGA, The Cancer Genome Atlas; TPM, transcripts per million. CEBPG enhances HeLa cell proliferation, migration, and invasion while suppressing apoptosis To explore the functional role of CEBPG in cervical cancer, we conducted overexpression experiments targeting CEBPG in the HeLa cell line. Successful upregulation of CEBPG was verified by RT-qPCR and Western blotting (Figure 2A,2B). Cell proliferation assays demonstrated that CEBPG overexpression significantly enhanced HeLa cell proliferation (Figure 2C). Flow cytometry analysis of apoptosis rates revealed that CEBPG overexpression suppressed apoptosis in HeLa cells (Figure 2D). Further migration and invasion assays indicated that CEBPG overexpression promoted both migration and invasion of HeLa cells (Figure 2E,2F). Collectively, these findings suggest that CEBPG exerts pro-oncogenic effects in cervical cancer HeLa cells. The elevated expression of CEBPG facilitates the viability, migration, and invasion of HeLa cells, while concurrently reducing cell death. (A) RT‑qPCR validation of CEBPG mRNA levels in HeLa cells overexpressing CEBPG. (B) Western blot analysis confirming successful CEBPG upregulation. (C) Cell proliferation results of CEBPG overexpression in HeLa cells. (D) Cell apoptosis detection of Hela after CEBPG overexpression. (E) Cell migration results of CEBPG overexpression in Hela cells (scale bar: 50 µm). (F) Cell invasion results of CEBPG overexpression in HeLa cells (scale bar: 50 µm). *, P<0.005; **, P<0.01; ***, P<0.001; ****, P<0.0001. CCK-8, Cell Counting Kit-8; NC, negative control; OD, optical density; RT-qPCR, reverse transcription quantitative polymerase chain reaction. CEBPG remodels the transcriptome of oncogenic signaling in HeLa cells To further explore the mechanism of action of CEBPG, we performed RNA-seq on cells with CEBPG overexpression. Principal component analysis (PCA) of all detected genes clearly separated the CEBPG overexpression group from the control group, suggesting a widespread effect of CEBPG on gene expression (Figure 3A). The volcano plot demonstrated that after CEBPG overexpression, 372 genes were upregulated and 123 genes were downregulated (Figure 3B). The expression clustering heatmap of these DEGs showed high consistency across three biological replicates (Figure 3C). The upregulated DEGs were enriched in the integrin complex, collagen-containing extracellular matrix, positive regulation of cell migration, cell adhesion mediated by integrin, and integrin-mediated signaling pathway in the GO database, and in the regulation of actin cytoskeleton pathway in the KEGG database, all of which are related to cell migration (Figure 3D, left). The downregulated DEGs were enriched in biological processes such as negative regulation of cell population proliferation, angiogenesis, positive regulation of cell migration, and positive regulation of cell population proliferation in the GO database, which are associated with cell metastasis and proliferation (Figure 3D, right). Furthermore, to better characterize the downstream pathways regulated by CEBPG, we performed GSEA on all detected genes. Notably, the CEBPG overexpression group showed significant enrichment of the HALLMARK_MYC_TARGETS_V1 and HALLMARK_MYC_TARGETS_V2 gene sets (Figure S1), consistent with the known role of CEBPG as a bZIP transcription factor. These findings indicate that CEBPG overexpression leads to noticeable changes in gene expression patterns in HeLa cells, specifically affecting genes associated with cell migration and metastasis-related pathways, which may in turn have an impact on the malignant characteristics of cancer cells. Transcriptomic analysis of CEBPG overexpression. (A) PCA of samples after normalizing all genes expression levels. The ellipses indicate the confidence region for each group. (B) Identification of DEGs between CEBPG overexpression and NC samples by volcano plot. Red points: upregulated genes; blue points: downregulated genes. (C) The heatmap showing the expression profiles. TPM values are log2-transformed and then median-centered by each gene. (D) Bubble plots showing the GO/KEGG enrichment results for up/down DEGs. BP, biological process; CC, cellular component; DEGs, differentially expressed genes; FDR, false discovery rate; GO, gene ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; MF, molecular function; NC, negative control; PCA, principal component analysis; TPM, transcripts per million Examination of CEBPG-mediated transcriptional regulatory targets As is well known, CEBPG is a transcription factor. Therefore, we also downloaded the transcriptional regulatory targets of CEBPG from the ENCODE database, the TFTG database, and the TRRUST database. Subsequently, we intersected these targets with the DEGs identified in our RNA-seq analysis. We found 27 potential transcriptional regulatory targets of CEBPG (Figure 4A). Among them, there were 16 upregulated genes and 11 downregulated genes (Figure 4B). To gain further insight into the biological functions of these 27 overlapping genes, we performed GO and KEGG enrichment analyses. The GO analysis revealed enrichment in biological processes including negative regulation of cell population proliferation and positive regulation of gene expression (Figure 4C, left). The KEGG pathway analysis showed enrichment in multiple pathways, including the IL-17 signaling pathway, TNF signaling pathway, NF-kappa B signaling pathway, and MAPK signaling pathway (Figure 4C, right). ANTXR2, CARF, EHD3, PDZK1IP1, and SULF1 showed upregulated expression, while XDH exhibited downregulated expression (Figure 4D). PDZK1IP1 was highly expressed in cervical cancer tissues (Figure 4E). Patients with high expression of the PDZK1IP1, ANTXR2, and SULF1 genes exhibit poor prognosis. Among these, PDZK1IP1 and ANTXR2 are significantly associated with the prognosis of cervical cancer patients (Figure 4F). The expression levels of PDZK1IP1, EHD3, and SULF1 were found to be higher in cervical cancer tissues compared to normal tissues (Figure 4G). These findings suggest that CEBPG may exert its oncogenic effects in cervical cancer by regulating the expression of these target genes. Identification and analysis of transcriptional targets regulated by CEBPG. (A) Venn diagrams of overlapping between DEGs and CEBPG transcriptional regulatory targets. (B) The heatmap showing the expression profiles of overlapped CEBPG transcriptional regulatory targets. (C) Bubble plots showing GO (left) and KEGG (right) enrichment results of the 27 overlapping genes. (D) The expression pattern and statistical difference of CEBPG transcriptional regulatory targets. Error bars represent mean ± SEM. *, P<0.05; ***, P<0.001. (E) Box plot showing the expression of PDZK1IP1 in TCGA-CESC normal and tumor samples. (F) Kaplan-Meier survival curve of the TCGA-CESC cohort based on PDZK1IP1, ANTXR2, and SULF1 expression. (G) The immunohistochemistry analysis of PDZK1IP1 (image available from https://www.proteinatlas.org/ENSG00000162366-PDZK1IP1/cancer/cervical+cancer#img), EHD3 (image available from https://www.proteinatlas.org/ENSG00000013016-EHD3/cancer/cervical+cancer#img), and SULF1 (image available from https://www.proteinatlas.org/ENSG00000137573-SULF1/cancer/cervical+cancer#img) in CESC or normal (scale bar: 50 µm). CESC, cervical squamous cell carcinoma; CI, confidence interval; DEGs, differentially expressed genes; GO, Gene Ontology; HR, hazard ratio; KEGG, Kyoto Encyclopedia of Genes and Genomes; N, node; NC, negative control; olp, overlap; SEM, standard error of the mean; T, tumor; TCGA, The Cancer Genome Atlas; TF, transcription factor; TPM, transcripts per million. CEBPG binds to the promoter regions of its predicted target genes To further investigate whether CEBPG directly binds to the promoters of its predicted target genes, we analyzed publicly available CEBPG ChIP-seq data from HepG2 cells (GEO: GSE95997 and GSE96281) (15). Using deepTools to analyze the aligned BAM files, we calculated the read density distribution of CEBPG across ±3 kb regions flanking the TSS and transcription end site (TES) and generated a heatmap. The results demonstrated that CEBPG binding signals were significantly enriched near the TSS (Figure 5A), suggesting that CEBPG is involved in the regulation of transcriptional initiation. Furthermore, analysis of the genomic feature distribution of CEBPG binding peaks revealed that they were predominantly located in promoter regions (Figure 5B). In addition, the distance distribution of binding peaks relative to the TSS showed that the vast majority of peaks were concentrated within the −1 kb to +1 kb range (Figure 5C), further confirming that CEBPG primarily binds to core promoter regions. Notably, we observed clear CEBPG binding peaks at the promoter regions of ANTXR2, CARF, and PDZK1IP1 (Figure 5D; Figure S2), all of which were identified as upregulated transcriptional targets of CEBPG in our RNA‑seq analysis. These findings suggest that CEBPG may bind to the promoter regions of these key target genes. CEBPG binds to the promoter regions of its predicted target genes (GSE95997 and GSE96281). (A) Heatmap showing CEBPG ChIP-seq read density distribution across ±3 kb regions flanking the TSS and TES. (B) Genomic feature distribution of CEBPG binding peaks. (C) Distance distribution of CEBPG binding peaks relative to the TSS. (D) Genome browser tracks showing CEBPG ChIP-seq binding peaks at the PDZK1IP1 locus. ChIP-seq, chromatin immunoprecipitation sequencing; TES, transcription end site; TSS, transcription start site Discussion Cervical cancer, a disease predominantly affecting middle-aged women, exhibits marked geographic disparities in incidence and mortality rates that are strongly modulated by regional economic status. Early cervical cancer often remains undiagnosed until advanced stages due to its asymptomatic course and lack of disease-specific manifestations (20). The dismal prognosis and limited treatment efficacy in advanced cervical cancer underscore the urgent need for novel prognostic, diagnostic, and therapeutic approaches (21,22). According to previous studies, CEBPG is overexpressed in various types of cancers and has been identified as a potential biomarker (9,23,24). While to our knowledge, no studies have explored the relationship between CEBPG expression and cervical cancer. In this study, we explored how CEBPG drives cervical cancer progression through its transcriptional regulatory activity. By analyzing the expression levels of CEBPG in cervical cancer data from the TCGA database, we observed that CEBPG is highly expressed in cervical cancer. Further functional studies revealed that overexpression of CEBPG in cervical cancer cell lines promotes cell proliferation, migration, and invasion while inhibiting apoptosis. The enrichment analysis of DEGs from the RNA-seq study with CEBPG overexpression revealed that these DEGs were enriched in pathways linked to tumorigenesis and progression, such as angiogenesis, cell proliferation, and cell migration. CEBPG facilitates cell cycle progression and suppresses cell differentiation, and is generally recognized as a proliferation-promoting transcription factor (25). Previous studies have demonstrated that CEBPG promotes lung cancer metastasis by upregulating the expression of CERS6 (10). Notably, in addition to its role in tumorigenesis and development, CEBPG also participates in wound repair by promoting cell migration (26). These findings collectively suggest that CEBPG functions as an oncogene in cervical cancer. To investigate how CEBPG transcriptionally regulates cervical cancer development, we leveraged RNA-seq data from CEBPG overexpression cells to preliminarily explore the transcriptional regulatory targets of CEBPG. By intersecting the CEBPG transcriptional regulatory targets documented in databases with the DEGs identified in the CEBPG-overexpression RNA-seq analysis, we identified 27 potential transcriptional regulatory targets of CEBPG. Among these, ANTXR2, CARF, EHD3, PDZK1IP1, and SULF1 exhibited upregulated expression, while XDH showed downregulated expression. Notably, ANTXR2 (27), EHD3 (28), CARF (29), and XDH (30) have all been confirmed to participate in the biological processes of tumor cell proliferation, migration, invasion, and apoptosis. PDZK1IP1 has been shown to enhance tumor cell stemness, thereby increasing their invasive and metastatic potential (31). SULF1 drives malignant phenotypes in cervical cancer through activation of the VEGFR2/PI3K/AKT axis (32). These findings suggest that CEBPG may contribute to the promotion of proliferation, migration, and invasion, as well as the inhibition of apoptosis in HeLa cells, by regulating the expression of these genes. This hypothesis provides novel clues and directions for a deeper understanding of the role of CEBPG in cervical cancer. Future studies should further explore the transcriptional regulatory relationships between CEBPG and these genes. Several limitations of this study should be acknowledged. First, all functional experiments were performed exclusively in HeLa cells; validation in additional cervical cancer cell lines (e.g., SiHa, CaSki) is necessary to confirm the consistency of the observed phenotypes. Second, our conclusions regarding the tumor‑promoting role of CEBPG are based solely on in vitro assays, including proliferation, apoptosis, migration, and invasion. While these findings are suggestive, they do not fully recapitulate the complex tumor microenvironment. In vivo experiments, such as nude mouse xenograft models, are essential to provide definitive evidence for the oncogenic function of CEBPG in cervical cancer. Third, the transcriptional regulatory relationships between CEBPG and its predicted targets identified in this study require further experimental validation, such as chromatin immunoprecipitation and dual‑luciferase reporter assays. Despite these limitations, our study provides novel insights into the potential role of CEBPG in cervical cancer and lays a foundation for future mechanistic and translational investigations. Conclusions In summary, this study demonstrates that CEBPG is highly expressed in cervical cancer. Overexpression of CEBPG in HeLa cells enhances proliferation, migration, and invasion while suppressing apoptosis. Transcriptomic analysis further reveals that CEBPG may exert its pro‑tumorigenic effects through the regulation of specific target genes. However, given the limitations of using a single cell line and the lack of in vivo validation, our findings should be interpreted as preliminary. Future studies using additional cell lines and animal models are warranted to confirm the oncogenic role of CEBPG and to explore its therapeutic potential. Supplementary The article’s supplementary files as Available at https://tcr.amegroups.com/article/view/10.21037/tcr-2026-0938/prf